A novel signaling axis of matriptase/PDGF-D/β-PDGFR in human prostate cancer

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9631-9640

  Ustach, Carolyn V ^a   Huang, Wei ^a   Conley LaComb, M Katie ^a   Lin, Chen Yong ^b   Che, Mingxin ^a,c   Abrams, Judith ^a   Kim, Hyeong Reh Choi ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; MATRIPTASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR D;

ANIMAL CELL; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION;

ANIMALS; BINDING SITES; CELL LINE; CELL LINE, TUMOR; HUMANS; IN SITU HYBRIDIZATION; LYMPHOKINES; MALE; MICE; MICROSCOPY, CONFOCAL; MUTATION; NIH 3T3 CELLS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 78649910284     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0511     Document Type: Article

References (49)

1. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312. (Pubitemid 351717519)
2. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302-9.
3. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-6. (Pubitemid 32422089)
4. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, et al. PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001;3:517-21.
5. Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004;23:3793-802. (Pubitemid 39389710)
6. Ustach CV, Kim HR. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 2005;25:6279-88.
7. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 1994;7:549-54.
8. George DJ, Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 2002;60:115-21; discussion 22.
9. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-9. (Pubitemid 29488934)
10. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
11. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-70. (Pubitemid 36432420)
12. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, et al. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001;7:800-5. (Pubitemid 32708713)
13. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64:4201-8. (Pubitemid 38802424)
14. Van Der Poel HG. Smart drugs in prostate cancer. Eur Urol 2004;45:1-17.
15. Sintich SM, Lamm ML, Sensibar JA, Lee C. Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor. Endocrinology 1999;140:3411-5.
16. Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res 2004;10:4192-7. (Pubitemid 38812500)
17. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-6. (Pubitemid 26372600)
18. Ustach CV, Taube ME, Hurst NJ Jr, Bhagat S, Bonfil RD, Cher ML, et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 2004;64:1722-9. (Pubitemid 38428694)
19. Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 1997;44:309-20. (Pubitemid 27419006)
20. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999;96:11054-61. (Pubitemid 29487326)
21. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999;274:18237-42.
22. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005;92:2171-80.
23. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 2006;15:217-27. (Pubitemid 43342167)
24. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5. (Pubitemid 36278444)
25. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, et al. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 2005;36:626-33.
26. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002;8:1101-7. (Pubitemid 35177362)
27. Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005;11:6202-7. (Pubitemid 43085066)
28. Friedrich R, Fuentes-Prior P, Ong E, Coombs G, Hunter M, Oehler R, et al. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem 2002;277:2160-8. (Pubitemid 34968802)
29. Lin CY, Wang JK, Torri J, Dou L, Sang QA, Dickson RB. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem 1997;272:9147-52. (Pubitemid 27154920)
30. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333-42.
31. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006;63:2968-78. (Pubitemid 46072302)
32. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, et al. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 2003;98:1898-904. (Pubitemid 37310232)
33. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720-5.
34. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003;36:49-59. (Pubitemid 36836256)
35. Ittman M, Mansukhani A. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997;157:351-6. (Pubitemid 26414989)
36. Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK, Van Veldhuizen PJ. Growth factors involved in prostate carcinogenesis. Front Biosci 2005;10:1355-67.
37. Tam NN, Chung SS, Lee DT, Wong YC. Aberrant expression of hepatocyte growth factor and its receptor, c-Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat. Carcinogenesis 2000;21:2183-91.
38. Algaba F, Trias I, Arce Y. Natural history of prostatic carcinoma: the pathologist's perspective. Recent Results Cancer Res 2007;175:9-24.
39. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 2005;108:1-11. (Pubitemid 40052280)
40. Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 2007;109:13-24. (Pubitemid 46120190)
41. Beard C, Schultz D, Loffredo M, Cote K, Renshaw AA, Hurwitz MD, et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:403-7. (Pubitemid 44332723)
42. Lee IH, Roberts R, Shah RB, Wojno KJ, Wei JT, Sandler HM. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 2007;68(4):1059-64. (Pubitemid 47048574)
43. Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 1989;142:763-8. (Pubitemid 19226718)
44. Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolov A, Chakraborty S, et al. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 2001;49:213-23.
45. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004;64:6082-90. (Pubitemid 39129408)
46. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323-9.
47. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-81. (Pubitemid 38756876)
48. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.
49. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.